Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
2.77 ^USD	-5.78%		+6.13%	+62.94%

May. 07	Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07	Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Heron Therapeutics, Inc. Provides Earnings Guidance for the Full Year of 2020

August 05, 2020 at 04:17 pm EDT

Heron Therapeutics, Inc. provided earnings guidance for the full year of 2020. For the period, the company is maintaining its 2020 guidance for net product sales for the CINV franchise of $70 million to $80 million.

Latest news about Heron Therapeutics, Inc.

Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target	Apr. 23	MT
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	Mar. 21	CI
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	Mar. 13	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	Mar. 13	MT
Heron Therapeutics Shares Soar After Q4 Results Beat	Mar. 13	MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $4, Keeps Buy Rating	Mar. 13	MT
Transcript : Heron Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M	Mar. 12	MT
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	Mar. 12	CI
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef	Jan. 24	DJ
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures	Jan. 24	MT
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures	Jan. 23	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Boeing 737 Max 9 Grounding	Jan. 08	MT
Heron Therapeutics Unveils Deal to Expand Sales Network for Postoperative Pain Control Anesthetic; Shares Rise Premarket	Jan. 08	MT
Heron Therapeutics, Inc. Enters into Five-Year Distributor Partnership with Crosslink Life Sciences, LLC to Expand the Sales Network Supporting ZYNRELEF	Jan. 07	CI
Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023	Dec. 21	CI
Heron Therapeutics Insider Bought Shares Worth $137,970, According to a Recent SEC Filing	Nov. 17	MT
Needham Trims Price Target on Heron Therapeutics to $4 From $5, Keeps Buy Rating	Nov. 15	MT
Transcript : Heron Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q3 Revenue $31.4M, vs. Street Est of $31.8M	Nov. 14	MT
Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024	Nov. 14	CI

Chart Heron Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Investor Day

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Heron Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.77 USD

Average target price

6.75 USD

Spread / Average Target

+143.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HERON THERAPEUTICS, INC.	+62.94%	417M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research